½ÃÀ庸°í¼­
»óǰÄÚµå
1419128

½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼® - º¸°í¼­ ¹üÀ§ : Á¦Ç° À¯Çüº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°

Cardiac Output Monitoring Devices Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product, Type, End User, and Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 1-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº 2022³â 14¾ï 9,800¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2030³â¿¡´Â 22¾ï 1,500¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö CAGRÀº 5.0%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÉÀåÀÇ ÁÂ½É½Ç ¶Ç´Â ¿ì½É½ÇÀÌ 1ºÐ¿¡ º¸³»´Â Ç÷¾×·®Àº ½É¹ÚÃâ·®À¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ½É¹ÚÃâ·®Àº ½ºÆ®·ÎÅ©·®°ú ½É¹Ú¼ö ¸ðµÎ¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. »ýü ÀÓÇÇ´ø½º, ¸Æ¹Ú À±°û ºÐ¼®, ¿­ Èñ¼®, FloTrac ¸ð´ÏÅ͸µ, PiCCO ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ, µµÇ÷¯, Ficks ¿ø¸®°¡ ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â¼úÀÇ ±âÃÊÀÔ´Ï´Ù. ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±âÀÇ »ç¿ëÀº ¼ö¼ú½Ç, ÁßÁõ Ä¡·á½Ç ¹× ±âŸ ȯ°æ¿¡¼­ ȯÀÚ¸¦ Æò°¡ÇÏ´Â µ¥ Áß¿äÇÕ´Ï´Ù. ±â¼ú °³¹ß ´öºÐ¿¡ ¸®Æ¬ Èñ¼®¹ýÀº ½Ç½Ã°£ ¿¬¼Ó ½É¹ÚÃâ·®(CO) ¸ð´ÏÅ͸µÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ¿¹Ãø±â°£À» ÅëÇØ ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº ÀÌ ±â¼ú·Î ±Þ°ÝÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

CVD¿¡ °É¸®±â ½¬¿î ³ë³â Àα¸ Áõ°¡´Â ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù.

½ÉÇ÷°ü Áúȯ(CVD) ¹× Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ ¹× ÁýÁß Ä¡·á°¡ ÇÊ¿äÇÑ ±âŸ ½É°¢ÇÑ °Ç°­ ¹®Á¦´Â ³ëÀÎ Àα¸¿¡¼­ Á¡Á¡ ´õ º¸ÆíÈ­µÇ°í ÀÖ½À´Ï´Ù. CVDÀÇ ÁÖ¿ä À§Çè ¿äÀÎÀº ³ªÀÌ, ¹ÎÁ·¼º, °¡Á··Â µîÀÔ´Ï´Ù. Èí¿¬, °íÇ÷¾Ð, °íÄÝ·¹½ºÅ×·Ñ, ºñ¸¸, ¿îµ¿ ºÎÁ·, ´ç´¢º´, ½Ä»ýȰ È¥¶õ, À½ÁÖ µîµµ À§Çè ¿äÀÎÀÔ´Ï´Ù.

±× °á°ú ÃßÁ¤±â°£ µ¿¾È ¼¼°è Àα¸ÀÇ °í·ÉÈ­°¡ ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ ¿¹Ãø¿¡ µû¸£¸é 2030³â±îÁö ¼¼°è¿¡¼­ 60¼¼ ÀÌ»óÀÇ Àα¸´Â 14¾ï¸íÀÌ µÈ´Ù°í ÇÕ´Ï´Ù. ³ªÀ̰¡ µé¼ö·Ï, »ç¶÷µéÀº À̵¿ÀÇ Á¦ÇÑÀ» ¹Þ±â ½¬¿öÁö¹Ç·Î, ´Ù¸¥ »ç¶÷¿¡ ÀÇÁ¸ÇÏ´Â °ÍÀ» ÇÇÇϱâ À§ÇØ ÀÇ·á º¸Á¶¿Í ¿øÁ¶°¡ ÇÊ¿äÇÏ°Ô µË´Ï´Ù. ¼¼°è Àα¸ÀÇ °í·ÉÈ­´Â ±Þ¼ÓÈ÷ ÁøÇàµÇ°í ÀÖÀ¸¸ç, ³ëÀÎÀÇ ¼ö´Â ÇâÈÄ ¼ö³â°£ Å©°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. 2020³â Àα¸Á¶»ç¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â 1920³âºÎÅÍ 2020³â±îÁö 65¼¼ ÀÌ»óÀÇ Àα¸°¡ Àüü Àα¸ Áõ°¡ÀÇ ¾à 5¹è ºü¸¥ ¼Óµµ·Î ±ÞÁõÇß½À´Ï´Ù. 2020³â¿¡´Â 5,580¸¸ ¸íÀÇ ¹Ì±¹ÀÎ, Áï ÃÑ Àα¸ÀÇ 16.8%°¡ 65¼¼ ÀÌ»óÀ̾ú½À´Ï´Ù. ¶ÇÇÑ ºê¶óÁú Àα¸ÀÇ 13%, Áï 3,000¸¸ ¸í ÀÌ»óÀÇ ³ëÀÎÀÌ 60¼¼ ÀÌ»óÀ̾úÀ¸¸ç, ÀÌ Àα¸´Â 2030³â±îÁö 5,000¸¸ ¸í, Áï ºê¶óÁú Àα¸ÀÇ 24%¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. µû¶ó¼­ CVD¿¡ °É¸®±â ½¬¿î ³ëÀÎ Àα¸ Áõ°¡´Â ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â Áß¿äÇÑ ¿äÀÎÀÌ µÇ¾ú½À´Ï´Ù.

ÇÑÆí, ȯÀÚ¿Í ÀÇ·á Àü¹®°¡µéÀº ƯÈ÷ ÄÄÇ»ÅÍ À̹ÌÁö ÃßÃâ ÀåÄ¡(CIEDs)¿Í °°Àº ±â±âÀÇ »çÀ̹ö º¸¾È °áÇÔÀ» ¿ì·ÁÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA)Àº 2023³â ¸ÞµåÆ®·Î´Ð»ç°¡ ¾à 35¸¸´ëÀÇ À̽ÄÇü ½ÉÀå ±â±â¸¦ ¸®ÄÝÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

FDA À¥»çÀÌÆ®¿¡ °ÔÀçµÈ ±Ç°í¿¡¼­´Â '¿¡³ÊÁö°¡ ÀúÇÏµÈ Ãæ°Ý ¶Ç´Â ÀüÇô Ãæ°ÝÀÌ ¾øÀ¸¸é »ý¸íÀ» À§ÇùÇÏ´Â ºÎÁ¤¸ÆÀ» ¼öÁ¤ÇÏÁö ¸øÇÒ ¼ö ÀÖÀ¸¸ç ½ÉÁ¤Áö, ±âŸ Áß»ó ¶Ç´Â Á×À½¿¡ À̸¦ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù'¶ó°í ¸»Çß½À´Ï´Ù. 'ÀÌ ±â±â¸¦ Âø¿ëÇÑ È¯ÀÚ°¡ ±â±â¸¦ Á¦°ÅÇÏ°í ±³Ã¼Çϱâ À§ÇØ Ãß°¡ ¼ö¼úÀ» ÇÊ¿ä·Î ÇÏ´Â °æ¿ì Ãß°¡ÀûÀÎ À§ÇØÀÇ À§ÇèÀÌ ÀÖ½À´Ï´Ù.' ¸ðµç ½ÉÀå À絿±â Ä¡·á Á¦¼¼µ¿±â(CRT-D)¿Í À̽ÄÇü Á¦¼¼µ¿±â(ICD)°¡ ÀÌ ¸®ÄÝÀÇ ´ë»óÀÌ µË´Ï´Ù. FDA¿¡ µû¸£¸é, ÀÌ·¯ÇÑ ±â±âÀÇ »ç¿ëÀº Áß»ó ¶Ç´Â »ç¸ÁÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ½ÃÀåÀÇ ¼ºÀåÀº ´Ù¼Ò ¾ïÁ¦µË´Ï´Ù.

½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº Á¦Ç°, À¯Çü ¹× ÃÖÁ¾ »ç¿ëÀÚ¿¡ ÀÇÇØ ±¸ºÐµË´Ï´Ù. ½ÃÀåÀº Á¦Ç°º°·Î ¼Ò¸ðǰ, ºÎ¼Óǰ, ±â±¸·Î ±¸ºÐµË´Ï´Ù. À¯Çüº°·Î ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº ħ½ÀÇü°ú ºñħ½ÀÇüÀ¸·Î ±¸ºÐµË´Ï´Ù. ÃÖÁ¾ »ç¿ëÀÚÀÇ °æ¿ì ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC) µîÀ¸·Î ±¸ºÐµË´Ï´Ù. Áö¿ªº°·Î ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ), À¯·´(¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, Çѱ¹, È£ÁÖ), ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«(¾Æ¶ø¿¡¹Ì¸®Æ®(UAE), »ç¿ìµð¾Æ¶óºñ¾Æ, ¾ÆÇÁ¸®Ä«, ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«), ³²¹Ì ¹× Áß¹Ì(ºê¶óÁú, ¾Æ¸£ÇîÆ¼³ª, ±âŸ ³²¹Ì ¹× ¾ÆÇÁ¸®Ä«)·Î ±¸ºÐµË´Ï´Ù.

Áö¿ªº°·Î º¼ ¶§ ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, Áß³²¹Ì·Î ³ª´¹´Ï´Ù. ºÏ¹Ì´Â ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±âÀÇ ¼ºÀå¿¡ °¡Àå Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¼ºÀåÀº ÀǾàǰ °³¹ß ±â¾÷¿¡ ÀÇÇÑ ÅõÀÚ Áõ°¡, ¹Ì±¹ Á¤ºÎ·ÎºÎÅÍÀÇ ´ë¾× º¸Á¶±Ý, ÁÖ¿ä ÀǾàǰ °³¹ß ±â¾÷ÀÇ °­ÇÑ Á¸Àç°¨, Á¤ºñµÈ ÇコÄɾî ÀÎÇÁ¶ó, ¸¸¼º Áúȯ Áõ°¡ µî ¿©·¯ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù.

Áö¿ªº°·Î º¸¸é ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº ÁÖ·Î ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿, ¾ÆÇÁ¸®Ä«, Áß³²¹Ì·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â ¼¼°è ½ÃÀåÀÇ ¼ºÀå¿¡ °¡Àå Å« ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù. ¼¼°èÀÇ ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå¿¡ ´ëÇØ ºÏ¹Ì´Â 2021³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ ¹è°æ¿¡´Â CVD À¯º´·ü Áõ°¡, °Ç°­ °ü¸® ºñ¿ë Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, °Ç°­ ÀÇ½Ä Áõ°¡, ÃÖ÷´Ü ÀÇ·á±â±â Á¢±Ù µîÀÌ ÀÖ½À´Ï´Ù.

Áúº´ °ü¸® ¿¹¹æ ¼¾ÅÍ(CDC) ¹× ½ÄǰÀǾ౹(FDA)Àº ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â¸¦ º¸°íÇÒ ¶§ ÂüÁ¶ÇÑ ÁÖ¿ä 1Â÷ ¹× 2Â÷ Á¤º¸¿øÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå »óȲ

  • PEST ºÐ¼®
  • »ýÅÂ°è ºÐ¼®
    • ¹ë·ùüÀÎÀÇ º¥´õ À϶÷

Á¦5Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå - ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ÁÖ¿ä ½ÃÀå ±âȸ
  • ÇâÈÄ µ¿Çâ
  • ¼ºÀå ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎÀÇ ¿µÇ⠺м®

Á¦6Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ¼¼°è ½ÃÀå ºÐ¼®

  • ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â-¼¼°è ½ÃÀå °³¿ä
  • ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â-¼¼°è ½ÃÀå ¹× ¿¹Ãø(-2030³â)

Á¦7Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Á¦Ç°º° ¼öÀÍ ºÐ¼®(2020-2030³â)

  • ¼Ò¸ðǰ ¹× ¾×¼¼¼­¸®
  • ±â±â

Á¦8Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : À¯Çüº° ¼öÀÍ ºÐ¼®(2020-2030³â)

  • ħ½À¼º
  • ºñħ½À¼º

Á¦9Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº° ¼öÀÍ ºÐ¼®(2020-2030³â)

  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦10Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Áö¿ªº° ¼öÀÍ ºÐ¼®(2020-2030³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ¿µ±¹
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • È£ÁÖ
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Áß³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ Áß³²¹Ì

Á¦11Àå COVID-19 ÀüÈÄÀÇ ¿µÇâ

Á¦12Àå ¾÷°è Á¤¼¼

  • ÇÕº´ ¹× Àμö
  • °è¾à, Á¦ÈÞ ¹× ÇÕÀÛ »ç¾÷
  • ½ÅÁ¦Ç° Ãâ½Ã
  • »ç¾÷ È®´ë ¹× ±âŸ Àü·«Àû Àü°³

Á¦13Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷ÀÇ È÷Æ®¸Ê ºÐ¼®
  • ±â¾÷ÀÇ Æ÷Áö¼Å´× ¹× ÁýÁßµµ

Á¦14Àå ½É¹ÚÃâ·® ¸ð´ÏÅ͸µ ±â±â ½ÃÀå - ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Getinge AB
  • GE Healthcare
  • ICU Medical, Inc.
  • Baxter International Inc.
  • Edward Lifesciences Corporation
  • LiDCO Group plc
  • Deltex Medical Group plc
  • Uscom
  • Osypka Medical GmbH
  • CNSystems Medizintechnik GmbH

Á¦15Àå ºÎ·Ï

AJY 24.02.14

The cardiac output monitoring devices market is expected to grow from US$ 1.498 billion in 2022 to US$ 2.215 billion by 2030; it is anticipated to record a CAGR of 5.0% from 2022 to 2030.

The amount of blood pumped by the heart's left or right ventricle in a minute is known as cardiac output. It is reliant on both stroke volume and heart rate. Bioimpedance, pulse contour analysis, thermodilution, FloTrac monitoring, PiCCO cardiac output monitoring, Doppler, and the Ficks principle are the foundations of cardiac output monitoring techniques. Using cardiac output monitoring devices is important in assessing patients in the operating room, critical care unit, and other settings. Thanks to technological developments, the lithium dilution approach has made continuous real-time cardiac output (CO) monitoring possible. Throughout the projection period, the market for cardiac output monitoring devices is anticipated to experience exponential growth for this technique.

The increasing geriatric population prone to CVD drives the growth of the cardiac output monitoring devices market.

Cardiovascular diseases (CVDs) and other significant health issues that require constant monitoring and intensive care are increasingly common in the senior population. A few main risk factors for CVD are age, ethnicity, and family history. Using smoke, having high blood pressure (hypertension), having high cholesterol, being obese, being inactive, having diabetes, having a poor diet, and drinking alcohol are additional risk factors.

As a result, over the estimated period, the world's aging population is expected to drive the cardiac output monitoring device market. According to World Health Organization (WHO) projections, by 2030, there will be 1.4 billion persons over 60 worldwide. With age, people become more susceptible to mobility limitations, as a result of which they require medical assistance or aid to avoid dependence on other individuals. The global population is aging rapidly, and the number of older adults is expected to increase significantly in the coming years. According to the 2020 Census, in the US, the population aged 65 and above surged nearly five times faster than the overall population growth during 1920-2020. In 2020, 55.8 million Americans, i.e., 16.8% of the total population, were aged 65 and above. Further, 13% of Brazil's population-more than 30 million seniors-is aged 60 or more; this population is expected to reach ~50 million by 2030, i.e., 24% of the country's population. Thus, the increasing geriatric population prone to CVD is a significant driver for the growth of the cardiac output monitoring devices market.

On the other hand, patients and healthcare professionals are particularly concerned about cybersecurity flaws in devices, particularly those like computerized image extraction devices (CIEDs), where there is a chance that the gadget may be reprogrammed or rendered inoperable. The Food and Drug Administration (FDA) of the United States stated in 2023 that Medtronic recalled around 350,000 implantable cardiac devices because of persistent problems with their capacity to provide high-voltage therapy when required.

An advisory on the FDA website states that "a reduced-energy shock, or no shock at all, may fail to correct a life-threatening arrhythmia, which can lead to cardiac arrest, other serious injury, or death." "If a patient with one of these devices requires additional surgical procedures to remove and replace the device, there are additional risks of harm." All cardiac resynchronization therapy defibrillators (CRT-Ds) and implanted cardioverter defibrillators (ICDs) with a glassed feedthrough produced after 2017 are covered by this recall. The use of these devices "may cause serious injuries or death," according to the FDA, which has classified this as a Class I recall. Thus, the market's growth would be somewhat restrained.

The cardiac output monitoring devices market is segmented based on product, type, and end user. The market is segmented into consumables, accessories, and instruments based on product. By type, the cardiac output monitoring devices market is segmented into invasive and non-invasive. End-user segments the cardiac output monitoring devices market into hospitals, ambulatory surgical centers, and others. Based on geography, the cardiac output monitoring devices market is divided into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Based on geography, the cardiac output monitoring devices market is divided into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America is the most significant contributor to the growth of cardiac output monitoring devices. This region's growth has been attributed to several factors, including increased investments made by drug development companies, large grants from the US government, a strong presence of major drug development companies, a well-developed healthcare infrastructure, and an increase in chronic diseases.

Based on geography, the cardiac output monitoring devices market is primarily segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America is the most significant contributor to the growth of the global market. Regarding the global market for cardiac output monitoring devices, North America held the biggest share in 2021. This can be attributed to the rise in the prevalence of CVDs, the increase in healthcare costs, the increase in disposable income, the rise in health consciousness, and the accessibility of cutting-ed

Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are key primary and secondary sources referred to while preparing the cardiac output monitoring devices report.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Cardiac Output Monitoring Devices Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Cardiac Output Monitoring Devices Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Cardiac Output Monitoring Devices Market - Global Market Analysis

  • 6.1 Cardiac Output Monitoring Devices - Global Market Overview
  • 6.2 Cardiac Output Monitoring Devices - Global Market and Forecast to 2030

7. Cardiac Output Monitoring Devices Market - Revenue Analysis (USD Million) - By Products, 2020-2030

  • 7.1 Overview
  • 7.2 Consumables and Accessories
  • 7.3 Instruments

8. Cardiac Output Monitoring Devices Market - Revenue Analysis (USD Million) - By Type, 2020-2030

  • 8.1 Overview
  • 8.2 Invasive
  • 8.3 Non-invasive

9. Cardiac Output Monitoring Devices Market - Revenue Analysis (USD Million) - By End User, 2020-2030

  • 9.1 Overview
  • 9.2 Hospitals
  • 9.3 Ambulatory Surgical Centres
  • 9.4 Others

10. Cardiac Output Monitoring Devices Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Cardiac Output Monitoring Devices Market Overview
    • 10.1.2 North America Cardiac Output Monitoring Devices Market Revenue and Forecasts to 2030
    • 10.1.3 North America Cardiac Output Monitoring Devices Market Revenue and Forecasts and Analysis - By Products
    • 10.1.4 North America Cardiac Output Monitoring Devices Market Revenue and Forecasts and Analysis - By Type
    • 10.1.5 North America Cardiac Output Monitoring Devices Market Revenue and Forecasts and Analysis - By End User
    • 10.1.6 North America Cardiac Output Monitoring Devices Market Revenue and Forecasts and Analysis - By Countries
      • 10.1.6.1 United States Cardiac Output Monitoring Devices Market
        • 10.1.6.1.1 United States Cardiac Output Monitoring Devices Market, by Products
        • 10.1.6.1.2 United States Cardiac Output Monitoring Devices Market, by Type
        • 10.1.6.1.3 United States Cardiac Output Monitoring Devices Market, by End User
      • 10.1.6.2 Canada Cardiac Output Monitoring Devices Market
        • 10.1.6.2.1 Canada Cardiac Output Monitoring Devices Market, by Products
        • 10.1.6.2.2 Canada Cardiac Output Monitoring Devices Market, by Type
        • 10.1.6.2.3 Canada Cardiac Output Monitoring Devices Market, by End User
      • 10.1.6.3 Mexico Cardiac Output Monitoring Devices Market
        • 10.1.6.3.1 Mexico Cardiac Output Monitoring Devices Market, by Products
        • 10.1.6.3.2 Mexico Cardiac Output Monitoring Devices Market, by Type
        • 10.1.6.3.3 Mexico Cardiac Output Monitoring Devices Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 France
    • 10.2.3 Italy
    • 10.2.4 Spain
    • 10.2.5 United Kingdom
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 Australia
    • 10.3.2 China
    • 10.3.3 India
    • 10.3.4 Japan
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 Middle East and Africa
    • 10.4.1 South Africa
    • 10.4.2 Saudi Arabia
    • 10.4.3 Rest of Middle East and Africa
  • 10.5 South and Central America
    • 10.5.1 Brazil
    • 10.5.2 Argentina
    • 10.5.3 Rest of South and Central America

11. Pre and Post Covid-19 Impact

12. Industry Landscape

  • 12.1 Mergers and Acquisitions
  • 12.2 Agreements, Collaborations, Joint Ventures
  • 12.3 New Product Launches
  • 12.4 Expansions and Other Strategic Developments

13. Competitive Landscape

  • 13.1 Heat Map Analysis by Key Players
  • 13.2 Company Positioning and Concentration

14. Cardiac Output Monitoring Devices Market - Key Company Profiles

  • 14.1 Getinge AB
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 14.2 GE Healthcare
  • 14.3 ICU Medical, Inc.
  • 14.4 Baxter International Inc.
  • 14.5 Edward Lifesciences Corporation
  • 14.6 LiDCO Group plc
  • 14.7 Deltex Medical Group plc
  • 14.8 Uscom
  • 14.9 Osypka Medical GmbH
  • 14.10 CNSystems Medizintechnik GmbH

15. Appendix

  • 15.1 Glossary
  • 15.2 About The Insight Partners
  • 15.3 Market Intelligence Cloud
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦